Notice

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Significant anti-tumor responses and reduction of brain metastases observedSEOUL, South Korea, June 2, 2025 /PRNewswire/ -- J INTS BIO, a company spec 2025.06.02

Notice

J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025

SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings 2025.04.30

Notice

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST Professor Joung Ho Kim join a pioneering collaboration in pre 2024.12.15

Notice

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy

SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ -- J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the 2024.10.24

Notice

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance

SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its s 2024.10.23

Notice

J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study

SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- J INTS BIO provided an update of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGF 2024.06.10

Notice

J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

SEOUL, South Korea, April 11, 2024 /PRNewswire/ -- J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation 2024.04.12

Notice

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

SEOUL, South Korea, Feb. 26, 2024 /PRNewswire/ -- J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Ge 2024.02.26

Notice

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

'JIN-A02', a 4th generation EGFR-TKI, is a substance that selectively binds to C797S, a mutation that leads to resistance to 3rd generation EGFR-TKIs 2024.01.01